NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading under the ticker GFOR, was a blank-check company sponsored by Graf & Company and formed to pursue a business combination in the life sciences and healthcare sector. The SPAC completed its initial public offering in 2021 and subsequently announced a merger target in NKGen Biotech, Inc., a clinical-stage biopharmaceutical company developing natural killer cell-based immunotherapies with a focus on neurodegenerative diseases including Alzheimer's. The September 2023 Form 8-K filing, carrying accession number 0001104659-23-101923, reflects a material corporate event tied to the closing period of that de-SPAC transaction, marking NKGen Biotech's transition to a publicly listed entity. Visit SpacDesk and sign up for full access to filing timelines, deal terms, and sponsor profiles for GFOR and hundreds of other SPACs.